Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden stomach cancer recurrence risk

NCT ID NCT07799649

Knowledge-focused Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study enrolls adults with stomach or gastroesophageal junction cancer who had a strong response to chemotherapy before surgery, with no or very little cancer left in the removed tissue. Researchers will use a personalized blood test that tracks tumor DNA to see if it can identify patients who still face a higher chance of the cancer coming back. The test results will not guide treatment, and doctors will follow standard care. The goal is to learn whether this monitoring approach can improve recurrence detection and survival outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tumor-informed ctDNA-MRD monitoring, a blood test that looks for tiny traces of tumor DNA to gauge recurrence risk
What this could lead to
If it works, this blood test could help doctors identify which stomach cancer patients need closer follow-up or extra treatment after surgery, even when standard tests look clear.
What could go wrong
This is an observational study, so it will not change anyone's treatment. The test may not reliably predict recurrence, and results depend on how well the blood test performs in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults treated at The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) with histologically confirmed gastric or gastroesophageal junction adenocarcinoma who have completed neoadjuvant therapy, undergone R0 gastrectomy, and achieved pathological complete response or major pathological response.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years. * Histologically confirmed gastric or gastroesophageal junction adenocarcinoma. * Completion of preoperative neoadjuvant therapy followed by R0 gastrectomy. * Postoperative pathological complete response, defined as Becker tumor regression grade 1a or Ryan tumor regression grade 0, or major pathological response, defined as Becker tumor regression grade 1b or Ryan tumor regression grade 1 with 10 percent or less residual viable tumor. * Willingness to undergo serial blood collection and follow-up and provision of written informed consent. * Eastern Cooperative Oncology Group performance status of 0 or 1 with adequate major organ function. * Adequate diagnostic biopsy or preoperative tumor tissue for 1021-gene panel testing. Exclusion Criteria: * Postoperative pathological assessment showing neither pathological complete response nor major pathological response, including more than 10 percent residual viable tumor or Becker tumor regression grade 2 to 3. * Distant metastatic disease identified intraoperatively or postoperatively. * Another malignant tumor within the previous 5 years. * Severe postoperative complications preventing any postoperative antitumor therapy. * Contraindication to immunotherapy, including active autoimmune disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric adenocarcinoma Gastroesophageal junction adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.